1152P - Amrubicin monotherapy in patients with platinum-refractory metastatic neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma of the gastr...

Date 27 September 2014
Event ESMO 2014
Session Poster Display session
Topics Anti-Cancer Agents & Biologic Therapy
Neuroendocrine Cancers
Presenter Tomonori Araki
Citation Annals of Oncology (2014) 25 (suppl_4): iv394-iv405. 10.1093/annonc/mdu345
Authors T. Araki1, T. Hamaguchi2, A. Takashima3, Y. Honma4, S. Iwasa4, N. Okita2, K. Kato5, Y. Yamada6, H. Hashimoto7, H. Taniguchi8, R. Kushima9, K. Nakao10, Y. Shimada11
  • 1Internal Medicine, National Hospital Organization Saga Hospital, 8498577 - Saga/JP
  • 2Gastrointestinal Oncology, National Cancer Center Hospital, JP-104-0045 - Tokyo/JP
  • 3Japan Clinical Oncology Group Data Center, Multi-institutional Clinical Trial Support Center, National Cancer Center, Tokyo/JP
  • 4Gastrointestinal Oncolgoy, national cancer center hospital, Tokyo/JP
  • 5Gastrointestinal Oncology, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 6Medical Oncology, National Cancer Center Hospital, JP-104-0045 - Tokyo/JP
  • 7Pharmacy, National Cancer Cneter Hospital, 104-0045 - Tokyo/JP
  • 8Division Of Pathology, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 9Division Of Pathology, National Cancer Center Hospital, JP-104-0045 - Tokyo/JP
  • 10Department Of Gastroenterology And Hepatology, Graduate School Of Biomedical Sciences, Nagasaki University, Nagasaki/JP
  • 11Gastrointestinal Oncolgoy, National Cancer Center Hospital, Tokyo/JP

Abstract

Aim

We conducted a retrospective anaysis to investigate the efficacy and safety of Amrubicin (AMR) in patients with platinum-refractory metastatic neuroendocrine carcinoma and mixed neuroendocrine carcinoma of the gastrointestinal tract (GIT-NEC/MANEC).

Methods

Patients with platinum-refractory extensive disease received AMR in the National Cancer Center Hospital between February 2004 and July 2012. AMR was administered 30-45 mg/m2 on days 1-3, and repeated every 3-4 weeks. The overall response rate (RR) was evaluated based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0, progression-free survival (PFS), overall survival (OS) were estimated by the Kaplan-Meier method, and adverse events based on Common Terminology Critera for Adverse Events (CTCAE) version 4.0.

Results

Twenty-one patients received AMR. After a median eight-month follow-up, RR for 18 patients was 22.2% (95% CI, 3.0-41.4), median PFS was 3.7 months (2.6-4.8), and median OS was 7.8 months (7.2-8.4). Grade 3/4 neutropenia occurred in 52.4% of patients, and febrile neutropenia in 14.3%. Other non-hematologic toxicities were mild and no treatment-related deaths were observed.

Conclusions

AMR displays tolerable toxicity and may be feasible and effective treatment of platinum-refractory GIT-NEC/MANEC patients. Further prospective evaluation of AMR for GIT-NEC/MANEC is warranted.

Disclosure

All authors have declared no conflicts of interest.